- Home
- THRY vs ENLV Comparison
THRY vs ENLV Comparison
Compare THRY & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THRY | ENLV |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 196.2M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | THRY | ENLV |
|---|---|---|
| Price | $3.72 | $0.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.33 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 917.2K | 406.4K |
| Earning Date | 04-30-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $0.66 |
| 52 Week High | $14.28 | $2.10 |
Technical Indicators
Market Signals| Indicator | THRY | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 40.72 |
| Support Level | $3.46 | $0.66 |
| Resistance Level | $4.17 | $1.23 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 43.32 | 24.86 |
Price Performance
Historical ComparisonAbout THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.